Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

High frequency of streptococcal bacteraemia during childhood AML therapy irrespective of dose of cytarabine.

Johannsen KH, Handrup MM, Lausen B, Schrøder H, Hasle H.

Pediatr Blood Cancer. 2013 Jul;60(7):1154-60. doi: 10.1002/pbc.24448. Epub 2012 Dec 31.

PMID:
23281248
2.

Predictors and outcomes of viridans group streptococcal infections in pediatric acute myeloid leukemia: from the Canadian infections in AML research group.

Lewis V, Yanofsky R, Mitchell D, Dix D, Ethier MC, Gillmeister B, Johnston D, Michon B, Stobart K, Portwine C, Silva M, Cellot S, Price V, Bowes L, Zelcer S, Brossard J, Beyene J, Sung L.

Pediatr Infect Dis J. 2014 Feb;33(2):126-9. doi: 10.1097/INF.0000000000000058.

PMID:
24064558
3.

Low incidence of sepsis due to viridans streptococci in a ten-year retrospective study of pediatric acute myeloid leukemia.

Brunet AS, Ploton C, Galambrun C, Pondarré C, Pages MP, Bleyzac N, Freydière AM, Barbé G, Bertrand Y.

Pediatr Blood Cancer. 2006 Nov;47(6):765-72.

PMID:
16333838
4.

Clinical features and complications of viridans streptococci bloodstream infection in pediatric hemato-oncology patients.

Huang WT, Chang LY, Hsueh PR, Lu CY, Shao PL, Huang FY, Lee PI, Chen CM, Lee CY, Huang LM.

J Microbiol Immunol Infect. 2007 Aug;40(4):349-54.

PMID:
17712470
5.

Viridans streptococcal sepsis: clinical features and complications in childhood acute myeloid leukemia.

Okamoto Y, Ribeiro RC, Srivastava DK, Shenep JL, Pui CH, Razzouk BI.

J Pediatr Hematol Oncol. 2003 Sep;25(9):696-703. Review.

PMID:
12972804
6.

Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG).

Lech-Maranda E, Seweryn M, Giebel S, Holowiecki J, Piatkowska-Jakubas B, Wegrzyn J, Skotnicki A, Kielbinski M, Kuliczkowski K, Paluszewska M, Jedrzejczak WW, Dutka M, Hellmann A, Flont M, Zdziarska B, Palynyczko G, Konopka L, Szpila T, Gawronski K, Sulek K, Sokolowski J, Kloczko J, Warzocha K, Robak T.

Int J Infect Dis. 2010 Feb;14(2):e132-40. doi: 10.1016/j.ijid.2009.02.021. Epub 2009 Jul 5.

7.

Viridans streptococcal bacteraemia due to penicillin-resistant and penicillin-sensitive streptococci: analysis of risk factors and outcome in 60 patients from a single cancer centre before and after penicillin is used for prophylaxis.

Spanik S, Trupl J, Kunova A, Botek R, Sorkovska D, Grey E, Studena M, Lacka J, Oravcova E, Krchnakova A, Rusnakova V, Svec J, Krupova I, Grausova S, Stopkova K, Koren P, Krcmery V Jr.

Scand J Infect Dis. 1997;29(3):245-9.

PMID:
9255883
8.

Viridans streptococci bacteraemia in children with fever and neutropenia: a case-control study of predisposing factors.

Paganini H, Staffolani V, Zubizarreta P, Casimir L, Lopardo H, Luppino V.

Eur J Cancer. 2003 Jun;39(9):1284-9.

PMID:
12763218
9.

[Infection control in neutropenia induced by high-dose cytarabine chemotherapy].

Miyazaki M, Senzaki K, Kiyoi H, Kohno S, Noda Y, Nabeshima T.

Gan To Kagaku Ryoho. 2004 Nov;31(12):2011-5. Japanese.

PMID:
15570930
10.

In vitro inferiority of ceftazidime compared with other beta-lactams for viridans group Streptococcus bacteremia in pediatric oncology patients: implications for antibiotic choices.

Paulus S, Dobson S, Rassekh S, Blondel-Hill E.

J Pediatr Hematol Oncol. 2009 Apr;31(4):267-9. doi: 10.1097/MPH.0b013e31819a5d40.

PMID:
19346878
11.

Infections with viridans group streptococci in children with cancer.

Reilly AF, Lange BJ.

Pediatr Blood Cancer. 2007 Nov;49(6):774-80. Review.

PMID:
17588233
12.
13.

Viridans group streptococcal infections among children with cancer and the importance of emerging antibiotic resistance.

Bruckner L, Gigliotti F.

Semin Pediatr Infect Dis. 2006 Jul;17(3):153-60. Review.

PMID:
16934710
14.

Development and validation of a clinical model to predict the presence of β-lactam resistance in viridans group streptococci causing bacteremia in neutropenic cancer patients.

Shelburne SA 3rd, Lasky RE, Sahasrabhojane P, Tarrand JT, Rolston KV.

Clin Infect Dis. 2014 Jul 15;59(2):223-30. doi: 10.1093/cid/ciu260. Epub 2014 Apr 21.

PMID:
24755857
15.

A randomized trial of high-versus conventional-dose cytarabine in consolidation chemotherapy for adult de novo acute myeloid leukemia in first remission after induction therapy containing high-dose cytarabine.

Bradstock KF, Matthews JP, Lowenthal RM, Baxter H, Catalano J, Brighton T, Gill D, Eliadis P, Joshua D, Cannell P, Schwarer AP, Durrant S, Gillett A, Koutts J, Taylor K, Bashford J, Arthur C, Enno A, Dunlop L, Szer J, Leahy M, Juneja S, Young GA; Australasian Leukaemia and Lymphoma Group.

Blood. 2005 Jan 15;105(2):481-8. Epub 2004 Jun 22.

16.

Clinical characteristics and antibiotic susceptibility of viridans streptococcal bacteremia in children with febrile neutropenia.

Han SB, Bae EY, Lee JW, Lee DG, Chung NG, Jeong DC, Cho B, Kang JH, Kim HK.

Infection. 2013 Oct;41(5):917-24. doi: 10.1007/s15010-013-0470-7. Epub 2013 May 3.

PMID:
23640200
17.

Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: a report from the Children's cancer group study CCG-2891.

Gamis AS, Howells WB, DeSwarte-Wallace J, Feusner JH, Buckley JD, Woods WG.

J Clin Oncol. 2000 May;18(9):1845-55.

PMID:
10784625
18.

[Infection caused by viridans streptococci in children with malignant hematologic diseases].

Rieske K, Handrick W, Spencker FB, Günther E.

Klin Padiatr. 1997 Nov-Dec;209(6):364-72. German.

PMID:
9445921
19.

Repetitive cycles of high-dose cytarabine are effective for childhood acute myeloid leukemia: long-term outcome of the children with AML treated on two consecutive trials of Tokyo Children's Cancer Study Group.

Tomizawa D, Tabuchi K, Kinoshita A, Hanada R, Kigasawa H, Tsukimoto I, Tsuchida M; Tokyo Children's Cancer Study Group.

Pediatr Blood Cancer. 2007 Aug;49(2):127-32.

PMID:
16807916
20.

Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors.

Bochud PY, Eggiman P, Calandra T, Van Melle G, Saghafi L, Francioli P.

Clin Infect Dis. 1994 Jan;18(1):25-31.

PMID:
8054434

Supplemental Content

Support Center